<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503867</url>
  </required_header>
  <id_info>
    <org_study_id>STX 0106</org_study_id>
    <nct_id>NCT00503867</nct_id>
  </id_info>
  <brief_title>SIR-Spheres速 for the Treatment of Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>A Pilot Study of Yttrium-90 Microspheres (SIR-Spheres速) Therapy for the Treatment of Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sirtex Medical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sirtex Medical</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety and toxicity of treatment with&#xD;
      SIR-Spheres速 in patients with unresectable primary liver cancer or hepatocellular carcinoma&#xD;
      (HCC). Other purposes of this study include assessment of the effect of treatment on overall&#xD;
      survival, the length of time it takes for the disease to worsen, if and how the treatment&#xD;
      affects the patient's quality of life, and if and how the cancer responds to the treatment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multi-institutional, non-randomized pilot study that aims to assess the&#xD;
      safety and toxicity of hepatic arterial radioembolization using SIR-Spheres yttrium-90&#xD;
      microspheres (SIR-Spheres microspheres) in the treatment of patients with unresectable&#xD;
      primary hepatocellular carcinoma (HCC). The study aims to recruit 40 patients over a period&#xD;
      of 24 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low patient recruitment&#xD;
  </why_stopped>
  <start_date type="Actual">July 18, 2007</start_date>
  <completion_date type="Actual">March 9, 2010</completion_date>
  <primary_completion_date type="Actual">March 9, 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Adverse Events Grade 3 or Higher</measure>
    <time_frame>From date of enrollment until the date of death from any cause assessed up 24 weeks.</time_frame>
    <description>Using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 3.0 as recorded in the case report form.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Disease Progression</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor Response Rate</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Tumour response rates estimated by the proportion of patients with a best response of CR, PR or SD by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) with corresponding exact 90% confidence limits being reported. Per RECIST v1.0 for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health-related Quality of Life</measure>
    <time_frame>52 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
    <description>Overall Survival is defined as the time interval between the date of enrollment and the date of death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Carcinoma, Hepatocellular</condition>
  <condition>Hepatoma</condition>
  <arm_group>
    <arm_group_label>SIR-Spheres microspheres</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SIR-Spheres microspheres</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SIR-Spheres microspheres</intervention_name>
    <description>SIR-Spheres Yttrium-90 microspheres</description>
    <arm_group_label>SIR-Spheres microspheres</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  must have a confirmed diagnosis of HCC.&#xD;
&#xD;
          -  at least 18 years of age.&#xD;
&#xD;
          -  must have a confirmed diagnosis of HCC either by histological confirmation or, in a&#xD;
             subject who exhibits a vascular liver mass in the presence of radiographically&#xD;
             apparent cirrhosis, an alpha-fetoprotein (AFP) level greater than 500 International&#xD;
             Units/milliliter (UI/ml).&#xD;
&#xD;
          -  must present HCC that is not amenable to surgical resection or immediate liver&#xD;
             transplantation, or that is not optimally treatable with local ablative techniques&#xD;
             such as radio-frequency ablation due to its size, extent or presence of cirrhosis.&#xD;
&#xD;
          -  must present measurable disease, defined as at least one lesion that can be accurately&#xD;
             measured in at least one dimension as greater than or equal to 10 mm with spiral CT&#xD;
             scan or greater than or equal to 20 mm using conventional techniques (CT, MRI).&#xD;
&#xD;
          -  must present with a whole-liver tumor burden of greater than or equal to 15% and less&#xD;
             than or equal to 70%&#xD;
&#xD;
          -  must have an Eastern Cooperative Oncology Group (ECOG) performance status of 2 or&#xD;
             less.&#xD;
&#xD;
          -  must have normal organ and marrow function&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Includes both the listed contraindications to SIR-Spheres速 and the exclusion criteria&#xD;
        specific to the setting of this investigational study:&#xD;
&#xD;
          -  hepatic artery directed therapy within the previous 6 months.&#xD;
&#xD;
          -  chemotherapy within the previous 4 weeks&#xD;
&#xD;
          -  have not recovered from adverse events due to agents administered previously&#xD;
&#xD;
          -  Prior external hepatic radiation therapy for HCC, more than two prior systemic&#xD;
             chemotherapy regimes for HCC or any other concomitant therapy for HCC&#xD;
&#xD;
          -  Currently receiving any other investigational agents for the treatment of their&#xD;
             cancer.&#xD;
&#xD;
          -  Any extra-hepatic metastases other than metastatic disease found in the lung, bone&#xD;
             and/or abdominal lymph nodes that are not otherwise life limiting.&#xD;
&#xD;
          -  Any other concurrent malignancy, except for adequately treated basal cell or squamous&#xD;
             cell skin cancer, in situ cervical cancer, or other cancer for which the patient has&#xD;
             been disease-free for at least five years.&#xD;
&#xD;
          -  Uncontrolled intercurrent illness or psychiatric illness/social situations that would&#xD;
             limit compliance with study requirements.&#xD;
&#xD;
          -  Any of the following contraindications to angiography and selective visceral&#xD;
             catheterization:&#xD;
&#xD;
               -  Bleeding diathesis&#xD;
&#xD;
               -  Severe peripheral vascular disease&#xD;
&#xD;
               -  Portal hypertension with hepatofugal flow&#xD;
&#xD;
          -  Female subjects who are pregnant or currently breastfeeding.&#xD;
&#xD;
          -  Refusal or inability to use effective means of contraception in men or women of&#xD;
             childbearing potential.&#xD;
&#xD;
          -  Current enrollment in any other investigational drug or device study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ravi Murthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>T. Clark Gamblin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UPMC Liver Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Thomas Jefferson University - Kimmel Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UPMC Liver Cancer Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Liver Institute at Methodist Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>July 18, 2007</study_first_submitted>
  <study_first_submitted_qc>July 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 19, 2007</study_first_posted>
  <results_first_submitted>March 22, 2017</results_first_submitted>
  <results_first_submitted_qc>November 16, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 10, 2020</results_first_posted>
  <last_update_submitted>November 16, 2020</last_update_submitted>
  <last_update_submitted_qc>November 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>unresectable hepatocellular carcinoma</keyword>
  <keyword>HCC</keyword>
  <keyword>SIR-Spheres</keyword>
  <keyword>Y-90 Microspheres</keyword>
  <keyword>brachytherapy</keyword>
  <keyword>Selective Internal Radiation Therapy (SIRT)</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Originally there was a plan to share the data with the Data Monitoring Committee, however the study was closed early due to lack of enrollment and the Data Monitoring Committee did not convene.</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Three medical centers in the US enrolled 10 patients from July 18, 2007 to March 9, 2010.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>SIR-Spheres Microspheres</title>
          <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hepatic Arterial Radioembolization SIR-Spheres Microspheres</title>
          <description>SIR-Spheres microspheres&#xD;
SIR-Spheres microspheres: SIR-Spheres Yttrium-90 microspheres</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" lower_limit="47.5" upper_limit="80.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG performance status</title>
          <description>Eastern Cooperative Oncology Group (ECOG) Performance Status</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0 (full activity)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1 (ambulatory restricted)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous chemotherapy</title>
          <description>1 cycle Nexavar, 800 mg BID</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Previous radiotherapy</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Yes</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease characteristics</title>
          <description>Hepatocellular carcinoma staging systems to determine prognosis included Okuda Staging, Cancer of the Liver Italian Program [CLIP]) &amp; tumor node metastasis (TNM) classification. Higher grades/score classes correlate to poorer prognosis.&#xD;
Okuda classification include cancer-related variables and liver function variables (Grade 1 to 3).&#xD;
CLIP staging combines Child-Pugh score with tumour criteria: morphology, portal invasion, &amp; alpha fetoprotein levels. (Stage 0 to 6).&#xD;
TNM staging describe size and/or extension of the primary tumor (Grade 1 to 4).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Okuda Stage 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLIP score Class 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLIP score Class 2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CLIP score Class Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cirrhosis (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNM Classification of Primary Tumor, T2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNM Classification of Primary Tumor, T3</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNM Classification of Primary Tumor, T4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNM Classification of regional lymph nodes (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis B (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatitis C (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metabolic Liver Disease (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of alcohol abuse (Yes)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>History of alcohol abuse (No)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adverse Events Grade 3 or Higher</title>
        <description>Using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 3.0 as recorded in the case report form.</description>
        <time_frame>From date of enrollment until the date of death from any cause assessed up 24 weeks.</time_frame>
        <population>Safety population - all patients who received initial SIRT treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>SIR-Spheres Microspheres</title>
            <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events Grade 3 or Higher</title>
          <description>Using the National Cancer Institute Common Terminology Criteria (NCI-CTC) version 3.0 as recorded in the case report form.</description>
          <population>Safety population - all patients who received initial SIRT treatment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Disease Progression</title>
        <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
        <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
        <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SIR-Spheres Microspheres</title>
            <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Disease Progression</title>
          <description>Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.</description>
          <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tumor Response Rate</title>
        <description>Tumour response rates estimated by the proportion of patients with a best response of CR, PR or SD by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) with corresponding exact 90% confidence limits being reported. Per RECIST v1.0 for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
        <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
        <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SIR-Spheres Microspheres</title>
            <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Tumor Response Rate</title>
          <description>Tumour response rates estimated by the proportion of patients with a best response of CR, PR or SD by Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) with corresponding exact 90% confidence limits being reported. Per RECIST v1.0 for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), &gt;=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.</description>
          <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health-related Quality of Life</title>
        <time_frame>52 weeks</time_frame>
        <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SIR-Spheres Microspheres</title>
            <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health-related Quality of Life</title>
          <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <description>Overall Survival is defined as the time interval between the date of enrollment and the date of death from any cause.</description>
        <time_frame>From date of enrollment until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 52 weeks.</time_frame>
        <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SIR-Spheres Microspheres</title>
            <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival</title>
          <description>Overall Survival is defined as the time interval between the date of enrollment and the date of death from any cause.</description>
          <population>This outcome measure was not assessed as no data was collected prior to termination of the study.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From consent until 24 weeks post last dose of protocol chemotherapy.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>SIR-Spheres Microspheres</title>
          <description>Radioembolization treatment with SIR-Spheres microspheres is administered within 28 days of enrollment into the study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Distention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>International Normalised Radio Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Director</name_or_title>
      <organization>Sirtex Medical</organization>
      <phone>011 61 2 9964 8470</phone>
      <email>dcade@sirtex.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

